NetworkNewsBreaks Archive - Page 2040 of 2141

MondayJun 12, 2017 12:20 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on BioSig Technologies, Inc. (BSGM)

SeeThruEquity has issued a company update and price target of $3.53 on shares of BioSig Technologies, Inc. (OTCQB: BSGM). Among other highlights, the SeeThruEquity analyst noted the recent expansion of BioSig’s collaboration agreement with the Mayo Clinic. The expanded technology and clinical development partnership has a 10-year term and includes cash warrants and licensing opportunities as well as joint intellectual property filings. The analyst also noted upcoming catalysts for the company, including BioSig’s plans to submit a 510(k) application for clearance to commercialize the PURE EP™ by the third quarter of 2017, and news that the company aims to up-list…

MondayJun 12, 2017 9:21 am

NetworkNewsBreaks – Nektar Therapeutics (NASDAQ: NKTR) Receives “Buy” Rating at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $27 on Nektar Therapeutics (NASDAQ: NKTR), stating that the company’s NKTR-214 has wide applicability and the ability to be combined effectively with multiple modalities such as checkpoint inhibitors, cell therapies, small molecules, or vaccines. The company has many upcoming catalysts, including an expansion of the Bristol-Myers Squibb Opdivo collaboration expected in the third quarter of 2017 and a collaboration with Roche Holding's Tecentriq trial that is expected to initiate by mid-2017. For more information, visit www.nektar.com About Nektar Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops…

MondayJun 12, 2017 9:19 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Ocera Therapeutics, Inc. (NASDAQ: OCRX)

Following Ocera Therapeutics, Inc.’s (NASDAQ: OCRX) Key Opinion Leader (KOL) conference call on hepatic encephalopathy and other complications of liver disease, Aegis Capital reiterated its ‘Buy’ rating and price target of $3 on shares of the company’s stock. The analyst noted the importance of OCR-002’s potential to reduce hospital stays by 1.5 days and believes that, combined with the IV formulation, the prospective savings for the hospitals could encourage them to adopt OCR-002 when available. Additionally, the company also recently initiated the dosing phase of its phase 1/2a trial of oral OCR-002 in cirrhosis. The end of phase 2 meeting…

MondayJun 12, 2017 9:17 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital has reiterated a ‘Buy’ rating and issued a price target of $25 on shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock. The news follows the company’s recent report of two patent wins in the EU. The Opposition Division (OD) of the European Patent Office has revoked another FibroGen, Inc. hypoxia-inducible factor (HIF) related patent in Europe. Additionally, Akebia’s challenge to a second HIF-related patent resulted in FibroGen considerably narrowing the claims to only cover an indication for vadadustat that Akebia does not intend to develop. The analyst noted its belief that the company now holds a strong IP position…

MondayJun 12, 2017 8:55 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Becomes Exclusive Licensee of Cannabis-Based Treatment for Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its entry into a definitive license agreement with the University of South Florida that makes the company the exclusive licensee of the U.S. patent filing entitled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’. If the patent filing is granted and proven, IGC anticipates that it could create a “significant therapeutic pathway” in the Alzheimer’s disease market, which is expected to record direct costs in excess of $450 billion annually in the next 12 years. “Securing this…

FridayJun 09, 2017 2:48 pm

NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Raises $5M in Private Placement; Proceeds will Fund Continued Development of Lead Candidate

AzurRx BioPharma (NASDAQ: AZRX) this morning announced the closing of a $5 million private placement that the company says will fund the continuation of its lead development program. “We are very grateful for the continued support of our investors and thrilled that the financing was over-subscribed,” AzurRx president and CEO Thijs Spoor stated in the news release. “This financing allows us to continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. In April, AzurRx said early results of its phase IIa trial of MS1819 indicated a favorable safety…

FridayJun 09, 2017 12:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 9, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CANN 8.40% – News: Acquires GC Finance Arizona, LLC IPIX 4.76% – News: Changes name and ticker PPCB 4.35% – News: Receives written opinion from an International Search Authority regarding PCT application EGLE 3.31% – News: Takes delivery of M/V Fairfield Eagle CIIX 1.90% – News: Highlighted in published CFN Media Group article AEZS 1.87% – News: Presenting at the 2017 Marcum MicroCap Conference on June 16 SHOS 1.79% – News: Announces multiple grand…

FridayJun 09, 2017 12:22 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $14 on shares of Novocure’s (NASDAQ: NVCR) stock following the company’s news that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM). The analyst said the additional coverage for Optune should result in a higher percentage of accrual-based revenue over time. The positive decision from HCSC brings the count of covered Americans to 204 million and is effective as of June 15, 2017. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment utilizing…

FridayJun 09, 2017 12:20 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Following Revance Therapeutics, Inc.’s (NASDAQ: RVNC) report of positive results from its phase 2 clinical study of RT002 to treat moderate-to-severe isolated cervical dystonia (CD), Aegis Capital reiterated its ‘Buy’ rating and price target of $36 on shares of the company’s stock. Additionally, Revance is in the process of enrolling for its pivotal, phase 3 Sakura trials. The identical trials taking place in the U.S. and Canada will randomize subjects 2:1 to receive either RT002 or placebo. The analyst noted that based off of the results seen in the phase 2 CD trial, they believe it is likely that the…

FridayJun 09, 2017 9:23 am

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) O2O Platform Mitigates SEO Burden and Helps SMEs Better Utilize E-Commerce

The Internet has been both a help and a hindrance to retailers – greatly extending their marketing reach and helping them target new customers, yet enabling faraway businesses to also beguile their customer base. Another challenge presented by the Internet is the difficulty of being visible within the sea of websites – more than 1.2 billion and quickly counting – which is where companies like Moxian (NASDAQ: MOXC) come in, offering solutions like the O2O Moxian+ platform to help small and medium-sized enterprises (SMEs) utilize e-commerce to drive customers to their brick-and-mortar locations and to cut down on the need…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks